Minimal-length synthetic shRNAs formulated with lipid nanoparticles are potent inhibitors of hepatitis C virus IRES-linked gene expression in mice

Molecular Therapy Nucleic Acids

Volumn 2, Issue SEP, 2013, Pages e123-

  Dallas, Anne ^a   Ilves, Heini ^a   Shorenstein, Joshua ^a   Judge, Adam ^b   Spitler, Ryan ^c   Contag, Christopher ^c   Wong, Suet Ping ^d   Harbottle, Richard P ^d   MacLachlan, Ian ^b   Johnston, Brian H ^a,c  

^a SomaGenics Inc   (United States)

^b Tekmira Pharmaceuticals Corporation   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

HCV; Lipid nanoparticles; PK; RNAi; shRNA; sshRNA

Indexed keywords

LUCIFERASE; NANOPARTICLE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNAL RIBOSOME ENTRY SITE; LIVER CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEASE PROTECTION ASSAY;

EID: 84890775092     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2013.50     Document Type: Article

References (38)

1. GraaGHCGWHO http://www.who.int/csr/disease/hepatitis/whocdcsrlyo2003/3n/ index4.htnl.
2. Armstrong, GL, Wasley, A, Simard, EP, McQuillan, GM, Kuhnert, WL and Alter, MJ (2006). The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714. (Pubitemid 46780630)
3. Perz, JF, Armstrong, GL, Farrington, LA, Hutin, YJ and Bell, BP (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529-538. (Pubitemid 44307383)
4. Wilson, JA, Jayasena, S, Khvorova, A, Sabatinos, S, Rodrigue-Gervais, IG, Arya, S et al. (2003). RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 100: 2783-2788. (Pubitemid 36297576)
5. Yokota, T, Sakamoto, N, Enomoto, N, Tanabe, Y, Miyagishi, M, Maekawa, S et al. (2003). Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep 4: 602-608. (Pubitemid 36939952)
6. Seo, MY, Abrignani, S, Houghton, M and Han, JH (2003). Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J Virol 77: 810-812. (Pubitemid 36005024)
7. Kanda, T, Steele, R, Ray, R and Ray, RB (2007). Small interfering RNA targeted to hepatitis C virus 5′ nontranslated region exerts potent antiviral effect. J Virol 81: 669-676. (Pubitemid 46067893)
8. Randall, G, Panis, M, Cooper, JD, Tellinghuisen, TL, Sukhodolets, KE, Pfeffer, S et al. (2007). Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 104: 12884-12889. (Pubitemid 47255249)
9. Vlassov, AV, Korba, B, Farrar, K, Mukerjee, S, Seyhan, AA, Ilves, H et al. (2007). shRNAs targeting hepatitis C: effects of sequence and structural features, and comparision with siRNA. Oligonucleotides 17: 223-236. (Pubitemid 47124419)
10. Ge, Q, Dallas, A, Ilves, H, Shorenstein, J, Behlke, MA and Johnston, BH (2010). Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA 16: 118-130.
11. Ge, Q, Ilves, H, Dallas, A, Kumar, P, Shorenstein, J, Kazakov, SA et al. (2010). Minimal-length short hairpin RNAs: the relationship of structure and RNAi activity. RNA 16: 106-117.
12. Wang, Q, Contag, CH, Ilves, H, Johnston, BH and Kaspar, RL (2005). Small hairpin RNAs efficiently inhibit hepatitis C IRES-mediated gene expression in human tissue culture cells and a mouse model. Mol Ther 12: 562-568. (Pubitemid 41150143)
13. Ilves, H, Kaspar, RL, Wang, Q, Seyhan, AA, Vlassov, AV, Contag, CH et al. (2006). Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice. Ann N Y Acad Sci 1082: 52-55. (Pubitemid 44955449)
14. Dallas, A, Ilves, H, Ge, Q, Kumar, P, Shorenstein, J, Kazakov, SA et al. (2012). Right- and left-loop short shRNAs have distinct and unusual mechanisms of gene silencing. Nucleic Acids Res 40: 9255-9271.
15. Aigner, A (2008). Cellular delivery in vivo of siRNA-based therapeutics. Curr Pharm Des 14: 3603-3619.
16. de Fougerolles, AR (2008). Delivery vehicles for small interfering RNA in vivo. Hum Gene Ther 19: 125-132.
17. Li, L and Shen, Y (2009). Overcoming obstacles to develop effective and safe siRNA therapeutics. Expert Opin Biol Ther 9: 609-619.
18. Li, SD and Huang, L (2008). Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances. Curr Opin Investig Drugs 9: 1317-1323.
19. Novobrantseva, TI, Akinc, A, Borodovsky, A and de Fougerolles, A (2008). Delivering silence: advancements in developing siRNA therapeutics. Curr Opin Drug Discov Devel 11: 217-224. (Pubitemid 351281061)
20. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
21. Wu, SY and McMillan, NA (2009). Lipidic systems for in vivo siRNA delivery. AAPS J 11: 639-652.
22. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178. (Pubitemid 39545841)
23. Zimmermann, TS, Lee, AC, Akinc, A, Bramlage, B, Bumcrot, D, Fedoruk, MN et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114.
24. Hoerter, JA, Krishnan, V, Lionberger, TA and Walter, NG (2011). siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract. PLoS ONE 6: e20359.
25. McCaffrey, AP, Meuse, L, Pham, TT, Conklin, DS, Hannon, GJ and Kay, MA (2002). RNA interference in adult mice. Nature 418: 38-39. (Pubitemid 34742563)
26. Kim, M, Shin, D, Kim, SI and Park, M (2006). Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. Virus Res 122: 1-10. (Pubitemid 44634825)
27. Collingwood, MA, Rose, SD, Huang, L, Hillier, C, Amarzguioui, M, Wiiger, MT et al. (2008). Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 18: 187-200. (Pubitemid 352019751)
28. Judge, AD, Robbins, M, Tavakoli, I, Levi, J, Hu, L, Fronda, A et al. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
29. Robbins, M, Judge, A, Ambegia, E, Choi, C, Yaworski, E, Palmer, L et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19: 991-999.
30. Judge, A and MacLachlan, I (2008). Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 19: 111-124. (Pubitemid 351271512)
31. Judge, AD, Bola, G, Lee, AC and MacLachlan, I (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13: 494-505. (Pubitemid 43257617)
32. Robbins, M, Judge, A and MacLachlan, I (2009). siRNA and innate immunity. Oligonucleotides 19: 89-102.
33. Bouchie, A (2012). Companies in footrace to deliver RNAi. Nat Biotechnol 30: 1154-1157.
34. Jeffs, LB, Palmer, LR, Ambegia, EG, Giesbrecht, C, Ewanick, S and MacLachlan, I (2005). A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 22: 362-372.
35. Semple, SC, Akinc, A, Chen, J, Sandhu, AP, Mui, BL, Cho, CK et al. (2010). Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 28: 172-176.
36. Yi, M, Wu, P, Trevorrow, KW, Claflin, L and Garrard, WT (1999). Evidence that the Igkappa gene MAR regulates the probability of premature V-J joining and somatic hypermutation. J Immunol 162: 6029-6039. (Pubitemid 29314961)
37. Xu, M, Hammer, RE, Blasquez, VC, Jones, SL and Garrard, WT (1989). Immunoglobulin kappa gene expression after stable integration. II. Role of the intronic MAR and enhancer in transgenic mice. J Biol Chem 264: 21190-21195. (Pubitemid 20017937)
38. Stein, Y, Halperin, G and Stein, O (1980). Biological stability of [3H]cholesteryl oleyl ether in cultured fibroblasts and intact rat. FEBS Lett 111: 104-106.